All posts tagged "PFE"
-
288Biotech$BIXT Spikes on Delayed Reaction to the Most Powerful Drug Since Penicillin
Bioxytran Inc. (OTCMKTS: BIXT) is perhaps one of the most undervalued biotechs in OTC. There is a real chance that if this...
-
5491BiotechNew CDC Guidelines Revive COVID Therapeutic Need for VERU TOMDF CYDY
If you thought COVID-19 was over, think again because the latest relaxation of pandemic measures by the CDC was dropped yesterday. The...
-
1.4KBiotechTodos (OTCMKTS: TOMDF) CEO Nails NewsMax Interview With Critical Messages About the Pandemic
This Saturday Todos Medical’s (OTCMKTS: TOMDF) CEO set the stage for future international media exposure. This interview was powerful, gripping, and informative...
-
615BiotechWhy Todos Medical (OTCMKTS: TOMDF) is Running Ahead of the Pack
Todos Medical (OTCMKTS: TOMDF) was a value play before it started running recently based on sound fundamental analysis, and now investors are...
-
438BiotechThe 3CL Secret to Pfizer’s and Todos Medical’s Success
Pfizer’s (NYSE: PFE) PAXLOVID has risen to prominence as the top COVID-19 antiviral in the world. The speed at which they rose...
-
5451BiotechPicking a Bottom in CytoDyn – Right Now
CytoDyn Inc (OTCMKT: CYDY) has been under considerable selling pressure since April and nothing seems to be able to stop it. In...
-
1.6KBiotechAtea Failure Leaves Todos Medical (TOMDF) Last Man Standing in Oral Antivirals
The big news circulating this week was of Atea Pharmaceuticals’ (NASDAQ: AVIR) COVID-19 antiviral clinical trial failure, which instantly plummeted the stock...
-
3971BiotechTodos Medical (TOMDF) COVID-19 Oral Antiviral Takes Death off Table
Todos Medical (OTCMKTS: TOMDF) today announced excellent Phase 1/2 results that appear to take dying from COVID-19 off the table. In a...
-
511BiotechTodos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral
Vaccines have less efficacy with COVID-19 variants Key 3CL protease inhibitors shows promise for any COVID-19 variants, and potentially all coronav...
-
2.7KBiotechAikido Pharma’s (AIKI) Clinical Trial Results Continues to Validates Gilead’s $21 Billion Purchase of Immunomedics
Aikido Pharma Inc. (NASDAQ: AIKI) announced excellent phase 1 data at the annual ASCO meeting. The data was presented by Dr. Scott...